Apogee Therapeutics Inc. (APGE)
NASDAQ: APGE
· Real-Time Price · USD
39.88
0.27 (0.68%)
At close: Oct 03, 2025, 3:59 PM
39.88
0.00%
After-hours: Oct 03, 2025, 04:20 PM EDT
0.68% (1D)
| Bid | 39.2 |
| Market Cap | 2.34B |
| Revenue (ttm) | 130K |
| Net Income (ttm) | -171.57M |
| EPS (ttm) | -4.14 |
| PE Ratio (ttm) | -9.63 |
| Forward PE | -7.12 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 41 |
| Volume | 545,639 |
| Avg. Volume (20D) | 733,703 |
| Open | 39.95 |
| Previous Close | 39.61 |
| Day's Range | 39.40 - 40.41 |
| 52-Week Range | 26.20 - 63.50 |
| Beta | 1.44 |
| Ex-Dividend Date | n/a |
About APGE
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol APGE
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for APGE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 months ago
-17.32%
APGE stock has given up its prior gain. Apogee The...
Unlock content with
Pro Subscription
3 months ago
-17.32%
Apogee Therapeutics shares are trading higher after the company released 16-week data from Part A of the Phase 2 APEX clinical trial of APG777 for moderate-to-severe atopic dermatitis.
2 months ago · seekingalpha.com
Apogee Therapeutics: Funding Supports Best-In-Class Ambitions In Atopic DermatitisApogee Therapeutics, Inc.'s APG777 shows best-in-class week-16 efficacy and quarterly/semi-annual dosing potential. In my view, this could give this drug candidate a great competitive profile. In fact...
2 months ago · proactiveinvestors.com
Apogee Therapeutics reports positive Phase 2 results for atopic dermatitis drugApogee Therapeutics (NASDAQ:APGE) shares fell almost 15% despite the release of positive Phase 2 APEX trial results for APG777, its anti-IL-13 antibody for moderate-to-severe atopic dermatitis. The tr...